stoxline Quote Chart Rank Option Currency Glossary
  
Zosano Pharma Corporation (ZSAN)
0.5576  0 (0%)    12-31 19:00
Open: 0.5188
High: 0.635
Volume: 1,155,058
  
Pre. Close: 0.5576
Low: 0.46
Market Cap: 0(M)
Technical analysis
2022-11-18 4:26:40 PM
Short term     
Mid term     
Targets 6-month :  0.74 1-year :  0.86
Resists First :  0.63 Second :  0.74
Pivot price 0.55
Supports First :  0.52 Second :  0.46
MAs MA(5) :  0.55 MA(20) :  0.55
MA(100) :  0.47 MA(250) :  0.79
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  55.7 D(3) :  55.7
RSI RSI(14): 64.4
52-week High :  7.63 Low :  0.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ZSAN ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 105 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.64 - 0.64 0.64 - 0.64
Low: 0.45 - 0.46 0.46 - 0.46
Close: 0.55 - 0.56 0.56 - 0.56
Company Description

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Headline News

Tue, 07 Jun 2022
Zosano goes bankrupt after FDA rejects drug delivery patch - FiercePharma

Thu, 02 Jun 2022
East Bay migraine patch developer files for bankruptcy - San Francisco Business Times - The Business Journals

Tue, 12 Apr 2022
Is Zosano Pharma (ZSAN) Stock Really Up 3000% Today? - InvestorPlace

Fri, 18 Mar 2022
Migraine patch developer Zosano cuts third of jobs after FDA rejection - San Francisco Business Times - The Business Journals

Tue, 22 Feb 2022
FDA Rejects Zosano Pharma's Application For Zolmitriptan Microneedle System Again, Shares Plunge - Yahoo Finance

Fri, 18 Dec 2020
Zosano Pharma Corporation Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 5 (M)
Held by Insiders 4.63e+006 (%)
Held by Institutions 5.4 (%)
Shares Short 370 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.93e+007
EPS Est Next Qtrly -0.24
EPS Est This Year -0.86
EPS Est Next Year -0.86
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -4 %
Return on Assets (ttm) 683 %
Return on Equity (ttm) -41.9 %
Qtrly Rev. Growth 659000 %
Gross Profit (p.s.) -14.84
Sales Per Share -58.66
EBITDA (p.s.) -6.3769e+006
Qtrly Earnings Growth -15.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -29 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.63
Stock Dividends
Dividend 0
Forward Dividend 393520
Dividend Yield 0%
Dividend Pay Date 2018-01-25
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android